Component
Haematologic response in TET2-mutant clonal cytopenia of undetermined significance
Response assessed by International Working Group Myelodysplastic Syndromes/Neoplasms criteria.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In a phase 2 trial of high-dose intravenous ascorbic acid in TET2-mutant clonal cytopenia of undetermined significance, none of the eight patients evaluable for response met International Working Group Myelodysplasia Syndromes/Neoplasms criteria at week 20.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- duration
- Response assessed at week 20
- experimental_model
- Phase 2 single-arm trial, 10 enrolled and 8 evaluable; NCT03418038
- exposure
- High-dose intravenous ascorbic acid
- limitations
- Eight evaluable patients and a 20-week assessment. A null in clonal cytopenia does not test prevention over years, nor treatment of established leukaemia, and the trial did not report whether TET2 activity or 5hmC changed.
- organism
- Homo sapiens
- plain_language
- In the one published trial of this idea in patients, nobody responded.
- primary_references
- [guarnera-2024] High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations (2024). https://pubmed.ncbi.nlm.nih.gov/39352751/ DOI: 10.1182/blood.2024024962
- tissue
- Blood and bone marrow
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
TET2 loss and malignancy: the step between a nutrient-responsive enzyme and the disease (2026-09-23) · lines 203–211
Original AI-assisted curation of twelve primary studies located by Europe PMC title search, with every statement drafted from the retrieved abstract. Two pairs share a laboratory and are recorded as one line of evidence each. Genetic loss of function, pharmacological exposure and dietary depletion are kept as separate record types. Not publisher full text. · supports · Phase 2 single-arm trial, 10 enrolled and 8 evaluable; NCT03418038 · source_derived_draft · unverified_draft
## ascorbate-no-response-in-ccus-trial In a phase 2 trial of high-dose intravenous ascorbic acid in TET2-mutant clonal cytopenia of undetermined significance, none of the eight patients evaluable for response met International Working Group Myelodysplasia Syndromes/Neoplasms criteria at week 20. Model/species: Phase 2 single-arm trial, 10 enrolled and 8 evaluable; NCT03418038 Organism: Homo sapiens Tissue/system: Blood and bone marrow Exposure: High-dose intravenous ascorbic acid Duration: Response assessed at week 20 Limits: Eight evaluable patients and a 20-week assessment. A null in clonal cytopenia does not test prevention over years, nor treatment of established leukaemia, and the trial did not report whether TET2 activity or 5hmC changed. Primary reference: [guarnera-2024] High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations (2024). https://pubmed.ncbi.nlm.nih.gov/39352751/ DOI: 10.1182/blood.2024024962
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.